DK0832093T3 - Udtrykkelse af lipoproteiner - Google Patents

Udtrykkelse af lipoproteiner

Info

Publication number
DK0832093T3
DK0832093T3 DK96918793T DK96918793T DK0832093T3 DK 0832093 T3 DK0832093 T3 DK 0832093T3 DK 96918793 T DK96918793 T DK 96918793T DK 96918793 T DK96918793 T DK 96918793T DK 0832093 T3 DK0832093 T3 DK 0832093T3
Authority
DK
Denmark
Prior art keywords
protein
lipidated
disclosed
leader sequence
heterologous
Prior art date
Application number
DK96918793T
Other languages
English (en)
Inventor
Maryanne B Gray
Robert C Huebner
Lorne F Erdile
Donald J Warakomski
Robert S Becker
Derek L Pyle
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of DK0832093T3 publication Critical patent/DK0832093T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96918793T 1995-06-07 1996-06-05 Udtrykkelse af lipoproteiner DK0832093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48637395A 1995-06-07 1995-06-07
US47578195A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
DK0832093T3 true DK0832093T3 (da) 2007-01-08

Family

ID=27044930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96918793T DK0832093T3 (da) 1995-06-07 1996-06-05 Udtrykkelse af lipoproteiner

Country Status (13)

Country Link
EP (2) EP1741718A3 (da)
JP (1) JP4091112B2 (da)
AT (1) ATE339436T1 (da)
AU (1) AU721954B2 (da)
CA (2) CA2223300C (da)
DE (1) DE69636544T2 (da)
DK (1) DK0832093T3 (da)
ES (1) ES2271954T3 (da)
FI (1) FI974422A (da)
IL (1) IL118578A (da)
NO (2) NO324089B1 (da)
PT (1) PT832093E (da)
WO (1) WO1996040718A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2313199A (en) 1998-02-03 1999-08-23 Center For Disease Control And Prevention Recombinant lipidated psaa protein, methods of preparation and use
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
DK1790660T3 (da) * 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Heterolog ekspression af Neisseria-proteiner
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2314314A3 (en) 2004-10-25 2011-05-11 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
CA2612900C (en) 2005-06-23 2016-08-09 Claus Aagaard Improved tuberculosis vaccines
EA013219B1 (ru) 2006-01-19 2010-04-30 Мэри Кэй, Инк. Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
PL2199303T3 (pl) 2008-12-12 2013-11-29 Euroimmun Medizinische Labordiagnostika Ag Polipeptydy i sposoby swoistego wykrywania przeciwciał u pacjentów z zakażeniem krętkami Borrelia
BRPI1006452A2 (pt) 2009-04-24 2016-12-27 Statens Seruminstitut vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
WO2011026039A1 (en) 2009-08-28 2011-03-03 Mary Kay Inc. Skin care formulations
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
WO1993008306A1 (en) * 1991-10-22 1993-04-29 Symbicom Aktiebolag Improvement in borrelia burgdorferi diagnosis and prophylaxis
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
WO1992014488A1 (en) * 1991-02-15 1992-09-03 Uab Research Foundation Structural gene of pneumococcal protein
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria

Also Published As

Publication number Publication date
IL118578A0 (en) 1996-10-16
DE69636544T2 (de) 2007-06-06
EP0832093A1 (en) 1998-04-01
PT832093E (pt) 2006-12-29
JP4091112B2 (ja) 2008-05-28
NO975619L (no) 1998-01-30
JPH11514841A (ja) 1999-12-21
NO20064621L (no) 1998-01-30
EP1741718A2 (en) 2007-01-10
DE69636544D1 (de) 2006-10-26
EP1741718A3 (en) 2007-03-28
CA2223300A1 (en) 1996-12-19
AU6134396A (en) 1996-12-30
EP0832093B1 (en) 2006-09-13
WO1996040718A1 (en) 1996-12-19
CA2223300C (en) 2010-07-27
EP0832093A4 (en) 2001-01-03
ATE339436T1 (de) 2006-10-15
AU721954B2 (en) 2000-07-20
NO975619D0 (no) 1997-12-04
FI974422A (fi) 1998-02-04
IL118578A (en) 2006-12-31
NO324089B1 (no) 2007-08-13
FI974422A0 (fi) 1997-12-05
CA2704354A1 (en) 1996-12-19
ES2271954T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
NO20064621L (no) Ekspresjon av lipoproteiner.
NO20004218D0 (no) Íkning av den sirkulerende halveringstiden til et antistoff- basert fusjonsprotein
NL1007028A1 (nl) Stabilisatorcombinatie.
FR2703239B1 (fr) Agrafe pour prothèse inter-épineuse.
DK0954588T3 (da) OB fusionsprotein-sammensætninger og fremgangsmåder
DE69925400D1 (de) Lasersystem-Steuerung
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
DE69735926D1 (de) Interleukin-18 Rezeptorproteine
DZ1763A1 (fr) Composition vaccinantes.
DE69708120D1 (de) Laser-absorbierende, lichtbleichbare zusammensetzungen
EP0608120A3 (en) Flow control device for capillary electrophoresis.
FR2702361B1 (fr) Fixateur pour les ostéosynthèses lombo-sacrées.
DE69528180D1 (de) Modifiziertes molkeprotein
IT1307309B1 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
DE69933509D1 (de) Roboter Steuerungssystem
DE19681312T1 (de) Datenverbindungs-Steuerverfahren
FI980735A (fi) Viiveenhallintamenetelmä
FR2710021B1 (fr) Selle perfectionnée.
HU9202074D0 (en) Collagen binding protein qnd method for producing it
FR2701833B1 (fr) Fixateur pour les ostéosynthèses lombo-sacrées.
ATE301713T1 (de) Plazentaprotein 13
TR27243A (tr) Antimikrobiyal proteinler.
ITRM930616A0 (it) Dispositivo perfezionato per il controllo di saldatura.
TR199600055A2 (tr) Eriyik isitma yöntemi.
FI970906A (fi) Säätelymenetelmä